Quantbot Technologies LP Acquires 5,926 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT)

Quantbot Technologies LP increased its holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 131.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,420 shares of the company’s stock after buying an additional 5,926 shares during the period. Quantbot Technologies LP’s holdings in Fulgent Genetics were worth $192,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Fulgent Genetics during the third quarter worth about $303,000. Intech Investment Management LLC bought a new stake in shares of Fulgent Genetics during the 3rd quarter worth approximately $272,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Fulgent Genetics during the 3rd quarter worth approximately $286,000. BNP Paribas Financial Markets boosted its position in shares of Fulgent Genetics by 220.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 43,813 shares of the company’s stock worth $952,000 after acquiring an additional 30,160 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Fulgent Genetics by 15.2% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,668 shares of the company’s stock valued at $971,000 after acquiring an additional 5,898 shares during the last quarter. 48.06% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CFO Paul Kim purchased 100,000 shares of the company’s stock in a transaction dated Wednesday, March 5th. The stock was bought at an average cost of $15.96 per share, for a total transaction of $1,596,000.00. Following the purchase, the chief financial officer now owns 348,282 shares of the company’s stock, valued at approximately $5,558,580.72. The trade was a 40.28 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 31.76% of the company’s stock.

Fulgent Genetics Trading Up 1.2 %

Shares of Fulgent Genetics stock opened at $17.05 on Monday. The firm’s 50 day moving average is $16.81 and its 200 day moving average is $18.64. The firm has a market capitalization of $526.27 million, a PE ratio of -3.09 and a beta of 1.54. Fulgent Genetics, Inc. has a 1 year low of $14.57 and a 1 year high of $25.11.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. StockNews.com upgraded Fulgent Genetics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 5th. Piper Sandler reduced their price objective on Fulgent Genetics from $22.00 to $16.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th.

Fulgent Genetics Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.